>
BELLUS Health Inc logo

BLU - BELLUS Health Inc Share Price

$4.36 -0.1  -1.1%

Last Trade - 5:06pm

Sector
Healthcare
Size
Small Cap
Market Cap £250.1m
Enterprise Value £180.0m
Revenue £10.8k
Position in Universe 3932nd / 6852
Bullish
Bearish
Unlock BLU Revenue
Momentum
Relative Strength (%)
1m +0.099%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -63.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
3.15 1.43 0.13 0.027 0.027 0.015 0.014 1.25 -65.7%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BELLUSHealth Inc revenues decreased 44% to $15K. Net lossincreased 22% to $31.8M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsResearch and development increase of 20% to $23.7M(expense), General and administrative increase of 48% to$9.7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BLU Revenue Unlock BLU Revenue

Net Income

BLU Net Income Unlock BLU Revenue

Normalised EPS

BLU Normalised EPS Unlock BLU Revenue

PE Ratio Range

BLU PE Ratio Range Unlock BLU Revenue

Dividend Yield Range

BLU Dividend Yield Range Unlock BLU Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BLU EPS Forecasts Unlock BLU Revenue
Profile Summary

BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company's pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 has the potential to help a number of chronic cough patients who do not respond to current therapies. BELLUS Health Inc also has economic interests in other partnered clinical-stage drug development programs, including KIACTA for sarcoidosis, AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer’s disease.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated April 12, 2012
Public Since September 15, 2014
No. of Shareholders: n/a
No. of Employees: 32
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market (Dual Listing)
Shares in Issue 78,337,361
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BLU Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BLU
Upcoming Events for BLU
Frequently Asked Questions for BELLUS Health Inc
What is the BELLUS Health Inc share price?

As of 5:06pm, shares in BELLUS Health Inc are trading at $4.36, giving the company a market capitalisation of £250.1m. This share price information is delayed by 15 minutes.

How has the BELLUS Health Inc share price performed this year?

Shares in BELLUS Health Inc are currently trading at $4.36 and the price has moved by -51% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BELLUS Health Inc price has moved by -67.79% over the past year.

What are the analyst and broker recommendations for BELLUS Health Inc?

Of the analysts with advisory recommendations for BELLUS Health Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BELLUS Health Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will BELLUS Health Inc next release its financial results?

BELLUS Health Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the BELLUS Health Inc dividend yield?

BELLUS Health Inc does not currently pay a dividend.

Does BELLUS Health Inc pay a dividend?

BELLUS Health Inc does not currently pay a dividend.

When does BELLUS Health Inc next pay dividends?

BELLUS Health Inc does not currently pay a dividend.

How do I buy BELLUS Health Inc shares?

To buy shares in BELLUS Health Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BELLUS Health Inc?

Shares in BELLUS Health Inc are currently trading at $4.36, giving the company a market capitalisation of £250.1m.

Where are BELLUS Health Inc shares listed? Where are BELLUS Health Inc shares listed?

Here are the trading details for BELLUS Health Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BLU
What kind of share is BELLUS Health Inc?

Based on an overall assessment of its quality, value and momentum, BELLUS Health Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BELLUS Health Inc share price forecast 2021?

Shares in BELLUS Health Inc are currently priced at $4.36. At that level they are trading at 56.77% discount to the analyst consensus target price of 0.00.

Analysts covering BELLUS Health Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.5660211787 for the next financial year.

How can I tell whether the BELLUS Health Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BELLUS Health Inc. Over the past six months, the relative strength of its shares against the market has been 48.61%. At the current price of $4.36, shares in BELLUS Health Inc are trading at 42.59% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BELLUS Health Inc PE Ratio?

We were not able to find PE ratio data for BELLUS Health Inc.

Who are the key directors of BELLUS Health Inc?

BELLUS Health Inc's management team is headed by:

Francesco Bellini - CHM
Roberto Bellini - PRE
Franklin Berger - IND
Pierre Larochelle - LED
Francois Desjardins - VFN
Denis Garceau - SVP
Tony Matzouranis - VBD
Youssef Bennani - IND
Clarissa Desjardins - IND
Sebastien Roy - SEC
Catherine Bonuccelli - OTH
Ramzi Benamar - CFO
William Mezzanotte - DRC
Who are the major shareholders of BELLUS Health Inc?

Here are the top five shareholders of BELLUS Health Inc based on the size of their shareholding:

Point72 Asset Management, L.P. Hedge Fund
Percentage owned: 7.94% (6.22m shares)
Avidity Partners Management LP Hedge Fund
Percentage owned: 7.31% (5.73m shares)
RTW Investments L.P. Investment Advisor/Hedge Fund
Percentage owned: 6.63% (5.19m shares)
Victoria Square Ventures Inc. Corporation
Percentage owned: 6.3% (4.94m shares)
Power Corporation of Canada Holding Company
Percentage owned: 6.3% (4.94m shares)
Similar to BLU
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.